Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMDL is also gone now, correct.
All evidence points to RXPC being gone forever. UNI and GCDx both got the IP for the fibrin test. The only fuel left for the takeover/merger fantasy is wishful thinking and a metaphysical belief that RXPC will be worth something again someday because, well, see a dictionary definition of metaphysical belief.
I see no reason to discuss any of this further unless something extraordinary happens, like Radient filing some financials with the SEC or some entity announcing they are resurrecting Radient. Not a chance of those things happening, so if people want to waste their time preaching about angels flying in on gossamer wings and offering cash for RXPC shares, I say, let them. No harm in it now.
Radient-pharmaceuticals.com has several pages that are just as valid as that "blank main page." Those Aussies apparently have been busy!
check these out - they all work just like the main page:
http://www.radient-diagnostics.com/stupid-americans-there-is-no-merger/
http://www.radient-diagnostics.com/your-money-is-gone-get-over-it/
Seems like there is a secret message in there somewhere. It's sort of like playing an old Beatles album backwards! What could it mean?
Provista has no LC test and no plans for one.
http://provistadx.com/provistaDx-News-2014.html
Quoting that article without the third paragraph below is taking it out of context, which leads to misunderstanding. Read it again -- it's a brief history of the company:
"Launched in 2004 as Provista Life Sciences, the company initially positioned itself as a mezzanine developer of molecular diagnostics that aimed to acquire early stage biomarker tests, advance them to the clinical stage, and then sell them.
In this manner it developed a diagnostics pipeline covering a number of disease areas including Alzheimer's, Parkinson's, ovarian cancer, and lung cancer. It also developed its original breast cancer test, called the BT Test, that it sold in Ireland and the UK through International Health Technology.
Upon becoming CEO in 2011, Reese refocused the company on women's cancers and began the process of revamping its breast cancer program. In January 2013, Provista launched a 350-patient prospective trial for its breast cancer early detection test, now called DtectDx Breast. That trial is evaluating the test in women under 50 years of age."
Let me paraphrase.
Paragraph 1: Provista started in 2004.
Paragraph 2: Provista worked on Alzheimer's, Parkinson's, ovarian cancer, and lung cancer.
Paragraph 3: Resse took over in 2003 and refocused on women's cancers.
This is not complicated. Provista is not working on lung cancer, Alzheimer's, or Parkinson's now. They are working on women's cancers. Their pipeline on their website proves this.
No lung cancer. No Radient. No DR-70. Anyone who doubts this needs to contact Provista and clear up their misconception.
There is nothing going on IMO.
A creeping merger does not take 3.5 years and an entity trying to orchestrate a creeping merger does NOT let the share registration get revoked.
UNI is happily selling the test without any involvement WITH or payments TO Radient, and if SRL wants more tests they can buy them from UNI.
GCDx is happily trying to sell the test in the USA without any involvement WITH or payments TO Radient.
The new Officers and Directors of Radient disappeared immediately after taking over.
RXPC shares are worthless and will always be worthless. But as long as the human mind can dream, there will be a discussion about a White Knight riding in on a Lipizzaner and saving RXPC shareholders.
Radient Diagnostics site has many pages up.
if http://www.radient-diagnostics.com is proof that "something is up" then these are also proof -- click on them to see what I mean.
For example, the Aussies apparently realize that Radient is a zombie:
http://www.radient-diagnostics.com/zombie/
And they seem to be acknowledging that RXPC shares will never trade again:
http://www.radient-diagnostics.com/RXPCwillnevertradeagain/
and they apparently are not supporting the merger theory:
www.radient-diagnostics.com/nomercynomerger/
Who cares what WG does? It does not affect RXPC in any way.
Provista has no plans for Radient and/or DR-70.
The only "gaps" are the missing pieces of evidence that any entity is merging with or taking over Radient.
Here's what's NOT missing: Facts. RXPC shares are revoked and worthless, the company declared insolvency and then the Corporation status became Void, the only marketable product went off patent, new Directors and Officers were appointed suddenly at the last minute and they promptly disappeared, and at least two entities that we know of -- GCDx and UNI -- are manufacturing and selling DR-70 off patent without paying Radient a dime.
Facts. Not wishful thinking that some white knight is going to ride in and offer RXPC shareholders money for their worthless shares.
Provista news releases regarding Radient are all from 2011 or earlier and are meaningless today.
Provista and Radient both have different CEO's now. Provista's new CEO bailed on the Radient merger and abandoned the Lung Cancer test to focus on "women's cancers."
"Positive Radient Scenarios" from ANY source have been fiction since Jade mutinied.
That LC reference was before 2011.
That PR has to be read in context:
"Launched in 2004 as Provista Life Sciences, the company initially positioned itself as a mezzanine developer of molecular diagnostics that aimed to acquire early stage biomarker tests, advance them to the clinical stage, and then sell them.
In this manner it developed a diagnostics pipeline covering a number of disease areas including Alzheimer's, Parkinson's, ovarian cancer, and lung cancer. It also developed its original breast cancer test, called the BT Test, that it sold in Ireland and the UK through International Health Technology.
Upon becoming CEO in 2011, Reese refocused the company on women's cancers..."
Reese abandoned the lung cancer test. Provista has no plans for LC or for Radient.
WG is doing exactly what he said he was going to do at AZBio.
He is trying to sell DR-70 on the internet as a lung cancer test.
WG said he had no personal or business relationship with Radient. That is proven now.
please post a link to the page on PDx website where it says they have a lung cancer test or are planning one someday.
Thanks!
Provista has no "Current Need for DR-70" and they do not have a lung cancer test.
Ask Provista. I did. Provista has nothing to do with RXPC.
When Provista releases the results of their breast cancer testing, this will be irrefutable. It's irrefutable NOW to those who have done the DD.
Knowledge is power.
RXPC is dead.
The text on that GCDX Order page changed to
"The Lung Cancer Test™ is available."
That TM is a lie - the trademark was abandoned. But more important: the PR said "All required Clinical Validation studies are complete with excellent results." Says who? Who would believe that without seeing the study details and the results? I question whether there even WAS a Validation Study.
Hopefully the FDA will make GCDx publish this "Validation Study" and explain how the results were "excellent."
The only thing we know for certain is: Radient is not involved, and RXPC shareholders will not benefit from anything GCDx does.
The two loudest cheers of the Radient Takeover Theorists were "it's all about the patent" and "Gartner the Leader is a biotech genius." Those cheers have fallen silent now that the patent is dead and Gartner is obviously on his own. So is anyone still cheering? If so, please explain what there is to cheer about.
What's left for Takeover Fantasy? Does it now rely solely on Provista using Radient's DR-70 in their tests? That misconception should be debunked soon when Provista releases their results and there is no mention of fibrin or fibrinogen.
As for CIT... I think Radient said it best when they said in the final 10K that CIT was worth nothing. I trust their judgement on that.
GCDx is trying to sell DR-70 and has no involvement with MacLellan or McRobbie-Johnson.
Any conjecture to the contrary requires evidence.
GCDx should just call it "LC Sentinel."
Provista wouldn't mind. Radient, of course, has no say in the matter.
Here's what GCDx says about their LC test on Fundable:
https://www.fundable.com/the-lung-cancer-test
"Utilizing these proprietary cancer biomarkers, coupled with a mathematical algorithm, The Lung Cancer Test can detect the presence of lung cancer in high-risk populations with a sensitivity of 87% and a specificity of 95%. The overall accuracy of the test is 97%, defined by the area under the receiver-operating characteristic (ROC) curve."
Here's what Provista said about LC Sentinel in 2010:
"The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. "
http://www.marketwired.com/press-release/radient-pharmaceuticals-provista-life-sciences-announce-new-blood-test-lung-cancer-nyse-amex-rpc-1334094.htm
Could this be any more obvious?
I thought GCDx was a smokescreen and a diversion?
It sure looks to me like GCDx is not a diversion or a smokescreen - it looks like GCDx fully intends to sell the DR-70 test without any involvement with Radient.
And why is there a TM after "The Lung Cancer Test" on this page?
http://globalcancerdx.com/Order.html
What lake? ands what "documentations?"
All the documentation I find says very clearly that LC Sentinel was Radient's reagents and nothing more. Here's my documentation -- please post yours and let's compare.
http://www.marketwired.com/press-release/radient-pharmaceuticals-provista-life-sciences-announce-new-blood-test-lung-cancer-nyse-amex-rpc-1334094.htm
"The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy."
That means DR-70, detection of fibrin and fibrinogen. Provista's test was nothing more.
"The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. "
Sound familiar? Gartner is using these numbers to pitch his lung cancer test to investors. His test is also DR-70 and nothing more.
As for Provista's breast cancer test -- the main selling point is that this test is specific to breast cancer. If Provista added "Radient reagents and biomarkers" to the test it would no longer be specific to breast cancer. That alone is proof enough for me that Provista's test does not use Radient's reagents.
But the irrefutable proof will be when Provista releases the abstract for their latest trials. That will tell whether their breast cancer test detects fibrin and/or fibrinogen. I look forward to the release of that abstract.
LC Sentinel was just DR-70.
Nothing more, nothing less. LC Sentinel was not some magical elixir combining DR-70 with anything else. This is evident from the old Radient PR's.
The name "LC Sentinel" might belong to Provista but who cares. Gartner's business GCDx is trying to sell DR-70 / LC Sentinel / "the Lung Cancer Test" / Onko-Sure / whatever name you want to throw on it. These are all names for the exact same thing.
Anyone who wants to manufacture or sell this test can do it now because Radient's patent expired and there is no pending patent application.
Provista's breast cancer test does not use DR-70 or anything else that involves Radient. Apparently, since Provista has not specifically stated this, it is the topic of debate for some reason. When Provista releases an abstract of their Breast Cancer Test study, the abstract will describe the science in no uncertain terms, and this "debate" will end.
As for Gartner being a VP of anything at Provista - that has nothing to do with Radient or RXPC. And Gartner IS USING DR-70 -- he can use DR-70 because it is not protected intellectual property any more.
Radient doesn't have a Global Distribution Network.
In every other country on the globe, Radient's distribution network failed to generate the minimum revenues specified in the distribution agreements.
SRL and UNI don't count. SRL never distributed for Radient or had any agreement with Radient. UNI doesn't have to pay Radient any more money, EVER, since DR-70 went off patent.
Bottom line, Radient could not sell DR-70. That's why the company failed.
regarding Gartner's "expensive validation study" -- nobody knows how much that cost or if it even started or what it entails. I doubt it has started and I doubt it will ever be completed.
Since we are treating Radient's 2010 PR's as if they were fresh news, let's look back to 1996:
http://online.liebertpub.com/doi/abs/10.1089/blr.1996.15.242?journalCode=blr
Key talking points: Brazil, $5.6 million guidance, actual revenues less than 5% of guidance.
That turned out to be the template for every "positive" press release for this company since 1996. Pick a country -- any country -- and predict $$$ millions in revenues. Results: less than 5% of guidance.
Three CEO's later (Dreher, MacLellan, Charter).... at least this new CEO isn't giving false guidance. That's a positive, I guess.
As for Radient and Provista in 2010... Provista got smart and backed out. Then the CEO at the time, Gartner, left Provista. Then Provista dropped their lung cancer test from their pipeline. The clinicals and trials for every other Provista test specifically omits DR-70 and/or onko-sure. Provista can't secretly be adding DR-70 to their test and not telling anyone. Science is science.
End of story. Provista has out of the Radient picture for a long time. Only Wishful Thinking can establish a tie between Radient and Provista now.
the Aussies have EVERYTHING to do with the lab equipment and every other aspect of Radient. They ARE Radient now.
And what aspect of Radient doesn't spell "DISASTER?" The only possible positives about Radient are fantastic unlikely things that have only one thing going for them: they cannot be proven wrong. Secret Takeover? Secret Merger? Resurrection? GCDx a smokescreen? Provista secretly paying Radient's debt? All absurdly unlikely, but they can't be proven wrong.
Here's what CAN be proven: Jade worth $0 instead of $20 million, delisting, lawsuits, defaulted loans, Sheriff's notices, insolvency, 12(j) share revocation, CEO and CFO resigning, patents expiring and new patent applications getting rejected, patent lawyers quit, new Officers and Directors shut down the website and phone lines and email addresses and disappear.
A landlord can ALWAYS get in.
Radient's landlord probably hasn't been paid since 2012. But it sounds like they were planning to sell the building and/or convert office space into condos so they apparently didn't care.
dcspka you said:
"Apparently Radient's equipment in its entirety (lab and office) has still remained in place."
I agree, Radient's lab and office seem to have been abandoned. That's common when companies become insolvent and stop paying rent and the landlord changes the locks and calls the sheriff.
I wonder if there is a file cabinet in that office covered in cobwebs and labeled "financial records."
I never thought the Aussies were going to file any missing financials but in light of this development it seems even LESS likely, if that were possible.
GCDx is a "smokescreen" for a Radient takeover?
What does that mean, exactly? Does that mean Gartner lying on Fundable, lied to the reporter who interviewed him, and lying in the recent press release?
The "Order" page got updated again. Check it out:
http://globalcancerdx.com/Order.html
Click on that "Buy Now" button and it takes you right to PayPal and would let you check out and send $124 to GCDx. If GCDx is a smokescreen as you claim, that is fraud.
As for Provista taking over Radient... Anyone who believes that doesn't realize how small a company Provista is. Radient was going to take THEM over in the 2010 PR's that are the sole basis of this takeover rumor.
Provista is slightly larger now... and they got smart about DR-70. They removed LC Sentinel from their pipeline and they have no plans to work with Radient, take over Radient, or use DR-70.
Ask Provista. I did. I'd rather base my decisions on facts than on wishful thinking.
True, these are facts about Radient.
They cannot be refuted in a counterpost.
The debate is about "is some entity trying to take over Radient?" and also about "Will RXPC shares ever trade again?"
These facts support the arguments that no entity is trying to take over Radient and RXPC will never trade again.
The proponents of the "Takeover argument" have no facts to support their theory -- no Schedule 13's showing institutional ownership, no communication from Radient or any other entity stating that Radient is being merged with, no proof that Radients' $18 million debt was paid off (just a statement by the company that they are insolvent), and no proof that anyone other than eTraders own the revoked RXPC stock.
The Takeover argument is remarkably unsupported by facts or logic - IMO it is supported by wishful thinking only. Nobody can communicate with the Radient Officers or Directors - nobody even knows which continent on which to look for them.
Here is the design for the new GCDx website "Order" subpages.
http://shop.globalcancerdx.com/
http://shop.globalcancerdx.com/about
http://shop.globalcancerdx.com/terms
http://shop.globalcancerdx.com/contact
http://shop.globalcancerdx.com/products
GCDx is still calling it the Lung Cancer Test - without a Trademark.
They are using PayPal. It's still on GoDaddy. No mention of Provista or Radient.
I hope this puts an end to the "GCDx and Radient and Provista joining hands and singing Kumbaya" fantasy.
Let me number it for REAL comprehension.
1."The order list is not the updated version Radient followers" makes no sense at all. If we are talking about the GCDx site here, then it's not about Radient at all and therefore off topic.
2, 3, 4, and 8. It doesn't matter what GCDx calls the DR-70 test or whether they get a trademark for it. The test GCDx wants to sell is DR-70 and nothing more. Who cares about a trademark?
Of course GCDX is not going to mention DR-70 because DR-70 is trademarked. The point is: GCDx can manufacture and sell DR-70 without being involved with Radient because DR-70 is off patent.
5 and 6. That email from Gartner is not "made up" and the GCDx website is not a hoax. All anyone has to do to verify that is contact Gartner. Simple. Gartner has no relationship, business or personal, with Radient and he has no reason to lie. The Takeover Rumor used to claim that the Takeover Entities were covering up to get shares cheaper -- ridiculous when RXPC traded and ludicrous now.
Accusing Provista of perpetuating a "hoax" on the GCDx website is libel. And absurd because Provista has private shareholders who could sue Provista if they did any such thing, and those shareholders could sue Provista if Provista secretly used any money to do anything hidden with Radient.
7. GCDx is setting up their own independent GoDaddy website to accept credit cards through PayPal. They had that "Buy it from our Store" page live for a day, then took it down, but when it was up, it was PayPal.
We are not even in square one, IMO. The board was folded up. The game didn't start over, the game ended.
I agree, it doesn't get any worse than this. Bankruptcy would have been better for Radient shareholders because in a bankruptcy the ticker still trades, at least for awhile.
And in a bankruptcy, Radient shareholders might have been treated to disclosure and known the truth about the debt and the absence of any kind of merger or takeover.
Revocation of Shares, by definition, should have ended the Creeping Backdoor Merger Rumor. Accumulating shares for a merger makes no sense if those shares are then revoked. So what will kill the rumor now?
If Provista doesn't mention Radient on their new website?
When the patent application status changes from Rejected to Abandoned?
The Aussies announcing a new company in Australia or Hong Kong?
I don't think any or all of those will kill the takeover rumor. If the rumor can live through Revocation of Shares and the Radient Corporation getting voided, the rumor cannot be killed.
So is the Radient debt repaid or not?
Yes or no.
The "Takeover Thesis" seems vague on this point. Sometimes the Takeover Theorists say the debt is all repaid. Now it seems that it's not repaid at all -- that lenders are holding revoked stock hoping it will some day be worth something.
The Takeover "Thesis" is too absurd to be taken seriously.
Nobody is EVER going to offer RXPC sareholders anything for your RXPC stock. They could have sold about 400 million to unsuspecting eTraders for .0001 after the revocation 8k was released but that opportunity has passed.
I understand the viewpoint in the 13th century that the sun orbited the earth. I also understand that RXPC shareholders are angry and hurt and confused. But I fail to see the benefit of dreaming up impossible scenarios that would result in RXPC someday again being worth something and presenting them on this message board as fact or even POSSIBILITIES.
As for "products promoted on an international basis" and "three cents a share" -- thankfully I was not drinking anything when I read that. 5 billion shares at three cents a share totals a market cap of $150 million - for THIS INSOLVENT COMPANY?
A summary of the Current Situation?
RXPC shares have been revoked and are worthless.
Radient Corporation is void.
Radient has no assets: they declared CIT to be worthless and the only other product, DR-70, went off patent.
No Schedule 13's proves there was no takeover underway before shares were revoked.
Radient declared they are insolvent in April 2014 and the last original Directors and Officers resigned.
No evidence whateoever that the $18 million debt was repaid. 2011 debt restructuring had no cash repayment plan - it was just shares, and the 5 billion shares could not have repaid more than a small fraction of that debt.
Provista denies any involvement with Radient and any use of Radient's products. GCDX denies any involvement with Radient, business or personal.
Current Officers and Directors were appointed when Radient declared insolvency and revoked the shares in April 2014 and those new Officers and Directors have literally disappeared. Ex-CEO MacLellan states that he has had no communication with them since he resigned in April 2014.
THAT is the current situation. Everything else is conjecture, rumor, and wishful thinking.
Agreed.
If the magical unicorn "Takeover Group" owns or controls RXPC shares, they had to do that when Radient was a public company and RXPC traded. There would be no other way to get the shares. So the argument that "Radient is a private company so it could be true" is nonsense.
The lack of Schedule 13's proves that no reporting entity (like the lenders) owns RXPC with the intent of taking over. There's no way around that rule. That's why there ARE Schedule 13's.
One of the proponents of the "Takeover Rumor" has claimed many times to "control" a billion shares on his own. Yes, he is probably lying, but that means he is lying about everything else, so let's pretend he is telling the truth for the sake of argument. That's 20% of the O/S right there. Who knows where the other 4 billion RXPC shares are scattered. The fact that nobody stepped forward to stop the revocation tells me that those 4 billion are scattered among retail traders who were holding RXPC hoping for another MJ rumor and didn't read that 8k.
That 8k said the revocation was due to 12(j), not 12(g), which means that Radient did not voluntarily revoke their shares - the SEC made them do it. That's the difference between 12(j) and 12(g).
When the patent application changes to ABANDONED in December 2014 I think we can stop hovering over this grave. Until then, I guess we stand here looking down at the sod waiting for a skeletal hand to poke through.
BOO!
Happy Halloween.
That "Restructuring" was 2011 and it Failed.
So much irony here. Where to begin?
Provista is not "gearing up for their lung cancer test and Radieny's [sic] CIT technology." A person could also say they are about to add generic Viagra and/or medical marijuana to their pipeline. Wishing out loud on a message board won't make any of this come true.
But what if Provista did want to work with CIT or DR-70? They could probably buy CIT from the Aussies for $200,000 and they can have DR-70 for free. The irony here is: if Provista did these things it would not benefit RXPC shareholders in any way -- in fact it would decrease the already slim chance that RXPC shares will ever trade again. So be careful what you wish for.
Yes, Radient is a private company. The irony here is: Provista can't "go public" through Radient because Radient is not a public company. Capiche?
It's ironic to tout the virtues of AMDL on this message board because RXPC shareholders do not own stock in AMDL. If AMDL rose from the ashes that would not benefit Radient or RXPC shareholders. RXPC shareholders need to wish with all their little hearts that the Aussies do not abandon the Radient Corporation and revive AMDL.
And the irony of mentioning "the Garza report" deserves its own book chapter. If anyone here has not read the "Garza Reports" they should drop everything and do that right now. Never has any stock "analyst" been so 100% wrong. He was wrong about EVERYTHING concerning Radient.
But the final and best irony here is: every link posted on this message board to 2010 and 2011 articles and stories and PR's shows that everything about Radient in 2010-2011 -- every PR, every Garza article, every Silvani interview, every CEO interview, every agreement -- was false.
The Aussies DO control Radient.
They are the only members of the Board of Directors and they are the only Officers. Legally they can do whatever they want with the company and its "assets."
They are under no obligation to do anything that anyone else wants them to do. RXPC shareholders don't even know upon which continent to start looking for them and there is no way to contact them.
There are no secret handshakes or clandestine agreements. This is just business. Radient failed, Radient died, R.I.P.
Time to face facts and Clearer Logic. Agreed. Here are the facts:
RXPC shares are revoked and worthless.
The Radient Corporation is voided in its state of incorporation.
Radient declared insolvency.
The Officers who authored all the "positive" Press Releases from 2009 - 2011 that keep appearing here HAVE ALL RESIGNED.
The new Officers cannot be contacted and have not made any attempt to communicate with the world about Radient. They started a Wordpress website but that website is not functional.
Radient has no assets - they declared CIT is worthless and their only other asset, DR-70, is now off patent. There are no pending patent applications.
As for the Clearer Logic: Either a person possesses the ability to reason logically, or they do not. As Ron White says, "You can't fix [that]." But I don't see any logical conclusion to be drawn from those facts other than: RXPC is dead.
Here's what I saw.
Feb 2013, SRL gets their hands on some expiring onko-sure tests and prints a hype "news article" about selling onko-sure in India. Retail investors did not realize that SRL had no agreement with Radient and their onko-sure sales meant nothing to Radient, so retail investors jumped on the volume momo and ran the RXPC pps from .0001 to .0004.
The PPS fell back to .0001 of course because hype does not sustain PPS.
Then in 2014 some Tweeters discovered that they could Tweet about zombie biotechs being "MJ Plays" because the zombie companies would not refute this. RXPC was just one of many zombie stocks that saw huge volume because of this MJ hype. RXPC shares once again spiked from .0001 to .0004 -- twice. Look at the chart.
The PPS stalled at .0004 each time because there was massive selling pressure. The lenders converted the last of the A/S and bagholders sold gratefully. After that second MJ rumor spike, all RXPC shares were firmly in the hands of retail investors -- and not just any retail investors, but specifically the new breed of eTraders who don't read 8k's and don't do their own DD.
Then out came the 8k announcing that Radient was insolvent and shares were being revoked. The new RXPC shareholders didn't read that 8k. There was another volume spike and this new breed of eTrader didn't care why - the PPS rose again!
The eTraders who made money flipping RXPC at .0004 on these volume spikes in 2014 put in buy orders for .0001 - about 500 million shares, a mere $50,000, peanuts on Wall Street. Since they don't do DD and don't read 8k's they didn't know that the company was about to disintegrate and the patent application was rejected. The eTraders who were holding the bag at .0004 weren't going to sell at .0001 for the same reasons.
I don't know why the educated RXPC shareholders who have been holding since 2011 didn't sell their shares for .0001 after that 8k was released. .0001 was better than nothing, and that 8k didn't leave anything to the imagination. Now they have nothing.
Radient has no assets. No entity is going to reinstate Radient. Biotech is all about money, not about curing cancer or saving the world.
To say that "the lack of a selloff after the 8k proves that there is a merger" shows a profound lack of market savvy, IMO. But that lack of savvy was a prerequisite for buying and/or holding RXPC after Radient admitted in 2011 that the Jade Holding was worthless, CIT was worthless, the India Deal was a lie, the Mayo Study was a lie, and NuVax was shut down because Radient couldn't pay Bhatia and Chang. I don't understand why anyone would hold after all that - any merger/takeover rumor should have died in 2011. Yet here we are today, discussing the merger rumor as if none of that had happened.
The eTraders who bought at .0001 and sold at .0004 on hype were the savvy ones, IMO. But the problem with zombie biotechs is: somebody always gets left holding the bag. Every stock is a pyramid scheme and some of them, like RXPC, collapse. Anyone who held RXPC after that revocation/insolvency 8k has to seriously re-evaluate their investment strategy, IMO.
Provista Diagnostics exists today with Reese as CEO.
This Provista has nothing whatsoever to do with Radient or DR-70.
The old Provista that signed agreements with Radient had Gartner as CEO. in 2012 the agreement you refer to here was between GCDx and Radient, not Provista and Radient.
Bottom line, whatever Provista did in 2009-2011 means nothing today. Whatever GCDx does today has no effect on RXPC shares. Whatever Provista does today has no effect on RXPC shares.
I get it, all right.
Whatever GCDx does has no effect on RXPC shares. Whatever Provista does has no effect on RXPC shares. Whatever UNI Pharma does has no effect on RXPC shares.
RXPC shares are revoked and worthless. Radient the corporation is voided. Nothing is going to bring back RXPC value.
RXPC shares are all in the hands of retail traders. Some of those traders are trying to perpetuate a takeover rumor. This rumor is unsubstantiated and ludicrous.
Yes, I get it, all right.
Provista researched Radient's DR-70 test (fibrin and fibrinogen degradation) in 2009 and 2010.
Currently, none of Provista's tests involve or incorporate DR-70.
They tried it, they abandoned it.
Anyone who doubts this should contact Provista to verify. I did. Knowledge is power.
Incidentally, GCDx can't start selling their version of DR-70 until they complete their Final "Validation Study," whatever that is.
And I doubt they actively started that "Validation Study." That looks like a sales pitch to me. A study that would appease the FDA would cost a lot of money and I don't think GCDx has funding. A GoDaddy site that uses PayPal to process payments is not a sign of a company that has funding.
I wonder if GCDx will ever provide more detail than they are providing in their marketing materials. A detailed description of the study would tell us whether GCDx's lung cancer test is just DR-70 and nothing more.